Form 4: Travere Therapeutics CFO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher R. Cline, CFO of Travere Therapeutics, sold shares to cover tax withholding obligations related to vested restricted stock units.
Summary
- Christopher R. Cline, the Chief Financial Officer of Travere Therapeutics, Inc., reported a transaction involving the sale of common stock on April 11, 2025.
- The sale was executed to cover tax withholding obligations associated with the settlement of vested restricted stock units.
- Cline sold 48 shares at a price of $13.1446 per share.
- Following the transaction, Cline still beneficially owns 89,990 shares of Travere Therapeutics common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral. The transaction is a routine sale to cover tax obligations, which is a common practice and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are generally not indicative of a negative outlook on the company's future performance.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it is a small transaction related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 04/11/2025 | Date of the stock sale transaction. |
| 04/14/2025 | Date of signature for the Form 4 filing. |
Keywords
Travere Therapeutics, TVTX, Christopher R. Cline, CFO, Form 4, SEC Filing, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.